Chronic Heart Failure: PBAC Recommends Empagliflozin

By Danélia Botes

April 14, 2023

Introduction:

The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction (LVEF ≤40%) starting April 1, 2022. Yet, the Pharmaceutical Benefits Advisory Committee (PBAC) decided in November 2022 not to endorse Empagliflozin for treating CHF in patients with a left ventricular ejection fraction over 40%. They based their decision on the high unmet clinical need and the economic model’s failure to capture the disease’s progressive nature adequately. A price reduction and risk sharing arrangement were required.

The PBAC has recommended an extension to the current empagliflozin listing on an updated addendum. This extension will include a General Schedule Authority Required (Streamlined) listing. It will be for the treatment of chronic heart failure in patients. These patients have a left ventricular ejection fraction greater than 40%. This recommendation comes after the sponsor addressed the outstanding issues. Also, the cost-effectiveness of the treatment is acceptable at the proposed price.

Empagliflozin’s Efficacy:

The PBAC observed a significant improvement in efficacy when adding Empagliflozin to standard care for this patient group. They based this observation on the primary composite outcome in EMPEROR-Preserved studies. These studies measured the time to the first cardiovascular death or hospitalisation for heart failure.

Addressing Outstanding Issues:

In conclusion, the sponsor has addressed significant outstanding issues identified in the November 2022 PBAC meeting. This was achieved through a proposed price reduction and risk sharing arrangement. The PBAC’s recommendation for listing was based on its assessment that the cost-effectiveness of Empagliflozin would be acceptable at the revised offer price of 16 December 2022.

Reference url

Recent Posts

early aortic stenosis surgery
        

Earlier Surgery Recommended for Heart-Valve Patients: New Study Insights

💔 Are we waiting too long for heart health interventions?

A recent study suggests that patients with severe aortic stenosis may benefit significantly from earlier surgical intervention, overturning traditional ‘wait and see’ practices. This shift, utilizing minimally invasive techniques, could prove vital in reducing unexpected hospitalizations and improving overall outcomes for patients, especially seniors. Learn more about this pivotal research that may redefine treatment protocols in cardiology!

#SyenzaNews #HealthcareInnovation #ClinicalTrials #MedTech #HealthTech

cross-border health surveillance
   

Strengthening Cross-Border Health Surveillance in Africa

🌍 How can enhanced cross-border surveillance improve public health security in Africa?

Check out the Africa CDC’s newly launched Strategic Framework that aims to bolster collaboration and information sharing among African Union Member States. This initiative tackles the challenges of health threats linked to population movement by promoting robust systems for surveillance and response. Discover how these efforts can pave the way for safer communities across the continent!

#SyenzaNews #globalhealth #HealthcareInnovation #DigitalTransformation #HealthTech

regional immunization framework
              

Strengthening Immunisation in the Eastern Mediterranean: WHO Launches Regional Framework

🌍 How can strengthening immunisation in the Eastern Mediterranean transform public health?

The recent launch of the regional framework by WHO is a crucial step towards enhancing vaccine access and addressing disparities in coverage. This initiative, inaugurated in Doha, aims to save millions of lives by ensuring everyone has access to essential vaccines, especially in conflict-affected areas. Discover how this framework can pave the way for healthier communities!

#SyenzaNews #GlobalHealth #HealthForAll #HealthcareInnovation #Immunisation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.